EKSO BIONICS HOLDINGS INC (EKSO) Fundamental Analysis & Valuation

NASDAQ:EKSO • US2826444000

Current stock price

10.15 USD
-0.75 (-6.88%)
At close:
10.97 USD
+0.82 (+8.08%)
After Hours:

This EKSO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. EKSO Profitability Analysis

1.1 Basic Checks

  • EKSO had negative earnings in the past year.
  • In the past year EKSO has reported a negative cash flow from operations.
  • In the past 5 years EKSO always reported negative net income.
  • In the past 5 years EKSO always reported negative operating cash flow.
EKSO Yearly Net Income VS EBIT VS OCF VS FCFEKSO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M

1.2 Ratios

  • EKSO has a Return On Assets of -59.28%. This is in the lower half of the industry: EKSO underperforms 69.84% of its industry peers.
  • EKSO's Return On Equity of -132.06% is on the low side compared to the rest of the industry. EKSO is outperformed by 68.25% of its industry peers.
Industry RankSector Rank
ROA -59.28%
ROE -132.06%
ROIC N/A
ROA(3y)-51.45%
ROA(5y)-42.63%
ROE(3y)-113.93%
ROE(5y)-86.01%
ROIC(3y)N/A
ROIC(5y)N/A
EKSO Yearly ROA, ROE, ROICEKSO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -200 -400 -600 -800

1.3 Margins

  • With a Gross Margin value of 53.48%, EKSO perfoms like the industry average, outperforming 51.32% of the companies in the same industry.
  • In the last couple of years the Gross Margin of EKSO has remained more or less at the same level.
  • The Profit Margin and Operating Margin are not available for EKSO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 53.48%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.6%
GM growth 5Y-1.3%
EKSO Yearly Profit, Operating, Gross MarginsEKSO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. EKSO Health Analysis

2.1 Basic Checks

  • EKSO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, EKSO has more shares outstanding
  • The number of shares outstanding for EKSO has been increased compared to 5 years ago.
  • The debt/assets ratio for EKSO is higher compared to a year ago.
EKSO Yearly Shares OutstandingEKSO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1M 2M 3M
EKSO Yearly Total Debt VS Total AssetsEKSO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M

2.2 Solvency

  • EKSO has an Altman-Z score of -17.36. This is a bad value and indicates that EKSO is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of EKSO (-17.36) is worse than 86.24% of its industry peers.
  • A Debt/Equity ratio of 0.31 indicates that EKSO is not too dependend on debt financing.
  • With a Debt to Equity ratio value of 0.31, EKSO perfoms like the industry average, outperforming 50.79% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Altman-Z -17.36
ROIC/WACCN/A
WACC10.26%
EKSO Yearly LT Debt VS Equity VS FCFEKSO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M

2.3 Liquidity

  • A Current Ratio of 1.63 indicates that EKSO should not have too much problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 1.63, EKSO is doing worse than 70.90% of the companies in the same industry.
  • EKSO has a Quick Ratio of 1.07. This is a normal value and indicates that EKSO is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Quick ratio value of 1.07, EKSO is not doing good in the industry: 75.13% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.63
Quick Ratio 1.07
EKSO Yearly Current Assets VS Current LiabilitesEKSO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. EKSO Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 42.57% over the past year.
  • EKSO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -28.60%.
  • Measured over the past years, EKSO shows a small growth in Revenue. The Revenue has been growing by 7.59% on average per year.
EPS 1Y (TTM)42.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.67%
Revenue 1Y (TTM)-28.6%
Revenue growth 3Y-0.29%
Revenue growth 5Y7.59%
Sales Q2Q%-38.31%

3.2 Future

  • Based on estimates for the next years, EKSO will show a very strong growth in Earnings Per Share. The EPS will grow by 22.46% on average per year.
  • The Revenue is expected to grow by 27.67% on average over the next years. This is a very strong growth
EPS Next Y91.48%
EPS Next 2Y40.98%
EPS Next 3Y26.12%
EPS Next 5Y22.46%
Revenue Next Year54.65%
Revenue Next 2Y28.81%
Revenue Next 3Y27.67%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
EKSO Yearly Revenue VS EstimatesEKSO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 10M 20M 30M
EKSO Yearly EPS VS EstimatesEKSO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 -100 -200 -300 -400

More info and screens

Find the best growth stocksShow best growing peers

1

4. EKSO Valuation Analysis

4.1 Price/Earnings Ratio

  • EKSO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year EKSO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EKSO Price Earnings VS Forward Price EarningsEKSO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EKSO Per share dataEKSO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

  • EKSO's earnings are expected to grow with 26.12% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.98%
EPS Next 3Y26.12%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. EKSO Dividend Analysis

5.1 Amount

  • EKSO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

EKSO Fundamentals: All Metrics, Ratios and Statistics

EKSO BIONICS HOLDINGS INC

NASDAQ:EKSO (3/27/2026, 5:43:02 PM)

After market: 10.97 +0.82 (+8.08%)

10.15

-0.75 (-6.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-23
Earnings (Next)05-04
Inst Owners15.41%
Inst Owner Change-1.76%
Ins Owners25.25%
Ins Owner Change0.42%
Market Cap36.13M
Revenue(TTM)12.80M
Net Income(TTM)-11.92M
Analysts80
Price Target9.69 (-4.53%)
Short Float %9.32%
Short Ratio0.82
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-151.88%
Min EPS beat(2)-357.52%
Max EPS beat(2)53.76%
EPS beat(4)2
Avg EPS beat(4)-75.19%
Min EPS beat(4)-357.52%
Max EPS beat(4)53.76%
EPS beat(8)4
Avg EPS beat(8)-48.29%
EPS beat(12)5
Avg EPS beat(12)-39.26%
EPS beat(16)7
Avg EPS beat(16)-30.81%
Revenue beat(2)0
Avg Revenue beat(2)-21.7%
Min Revenue beat(2)-38.74%
Max Revenue beat(2)-4.65%
Revenue beat(4)0
Avg Revenue beat(4)-31.27%
Min Revenue beat(4)-53.24%
Max Revenue beat(4)-4.65%
Revenue beat(8)0
Avg Revenue beat(8)-23.22%
Revenue beat(12)3
Avg Revenue beat(12)-11.29%
Revenue beat(16)3
Avg Revenue beat(16)-11.24%
PT rev (1m)0%
PT rev (3m)22.58%
EPS NQ rev (1m)0%
EPS NQ rev (3m)46.51%
EPS NY rev (1m)0%
EPS NY rev (3m)43.06%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.82
P/FCF N/A
P/OCF N/A
P/B 4
P/tB 7.09
EV/EBITDA N/A
EPS(TTM)-4.91
EYN/A
EPS(NY)-0.42
Fwd EYN/A
FCF(TTM)-3.37
FCFYN/A
OCF(TTM)-3.31
OCFYN/A
SpS3.6
BVpS2.54
TBVpS1.43
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -59.28%
ROE -132.06%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 53.48%
FCFM N/A
ROA(3y)-51.45%
ROA(5y)-42.63%
ROE(3y)-113.93%
ROE(5y)-86.01%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.6%
GM growth 5Y-1.3%
F-Score3
Asset Turnover0.64
Health
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 11.95%
Cap/Sales 1.47%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.63
Quick Ratio 1.07
Altman-Z -17.36
F-Score3
WACC10.26%
ROIC/WACCN/A
Cap/Depr(3y)7.83%
Cap/Depr(5y)11.11%
Cap/Sales(3y)0.84%
Cap/Sales(5y)0.91%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.67%
EPS Next Y91.48%
EPS Next 2Y40.98%
EPS Next 3Y26.12%
EPS Next 5Y22.46%
Revenue 1Y (TTM)-28.6%
Revenue growth 3Y-0.29%
Revenue growth 5Y7.59%
Sales Q2Q%-38.31%
Revenue Next Year54.65%
Revenue Next 2Y28.81%
Revenue Next 3Y27.67%
Revenue Next 5YN/A
EBIT growth 1Y-25.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-21.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-19.86%
OCF growth 3YN/A
OCF growth 5YN/A

EKSO BIONICS HOLDINGS INC / EKSO Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for EKSO BIONICS HOLDINGS INC?

ChartMill assigns a fundamental rating of 2 / 10 to EKSO.


What is the valuation status for EKSO stock?

ChartMill assigns a valuation rating of 1 / 10 to EKSO BIONICS HOLDINGS INC (EKSO). This can be considered as Overvalued.


What is the profitability of EKSO stock?

EKSO BIONICS HOLDINGS INC (EKSO) has a profitability rating of 1 / 10.


Can you provide the financial health for EKSO stock?

The financial health rating of EKSO BIONICS HOLDINGS INC (EKSO) is 2 / 10.


Can you provide the expected EPS growth for EKSO stock?

The Earnings per Share (EPS) of EKSO BIONICS HOLDINGS INC (EKSO) is expected to grow by 91.48% in the next year.